GlassScriptPhysician profile
Sudhakar L Reddivalam
NPI 1003969429
$13,529.38
in general payments reported to CMS, 2019-2025
34 companies · $2,004 in 2025
The $2,004 reported for 2025 was more than what 93% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,923 · 2020: $400 · 2021: $995 · 2022: $1,903 · 2023: $1,976 · 2024: $2,327 · 2025: $2,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,149 · Consulting Fee: $1,056 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,148.66 |
| Consulting Fee | $1,056.00 |
| Education | $102.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,893.53 | 2019-2025 | Dupixent |
| Pari Respiratory Equipment, INC. | $1,646.13 | 2019 | |
| Abbvie INC. | $1,590.95 | 2019-2025 | |
| Vertex Pharmaceuticals Incorporated | $867.51 | 2019-2025 | Trikafta |
| Astrazeneca Pharmaceuticals LP | $858.67 | 2019-2025 | Tezspire, Fasenra |
| Chiesi USA, INC. | $789.46 | 2019-2023 | Bronchitol, Pertzye |
| Glaxosmithkline, LLC. | $594.64 | 2019-2025 | Nucala |
| Digestive Care, INC. | $523.42 | 2023-2025 | Pertzye |
| Advanced Respiratory, INC | $450.81 | 2019-2021 | |
| Philips North America LLC | $450.15 | 2019-2025 | Vest Therapy Und, (8874) Incourage |
| Baxter Healthcare | $433.40 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Electromed, INC. | $391.09 | 2021-2025 | Smartvest |
| Genentech USA, INC. | $286.17 | 2019-2024 | Xolair |
| Gilead Sciences, INC. | $225.12 | 2019-2021 | |
| Amgen INC. | $203.75 | 2022-2025 | Tezspire |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $182.79 | 2022-2023 | |
| Inspire Medical Systems, INC. | $153.06 | 2023 | Inspire |
| Allergan, INC. | $141.07 | 2019 | |
| Mylan Specialty L.P. | $136.54 | 2019-2023 | Tobi Podhaler |
| Sobi, INC | $101.96 | 2019-2020 | |
| Genzyme Corporation | $85.33 | 2019-2025 | |
| Pharming Healthcare, INC. | $77.76 | 2022-2025 | Ruconest |
| Aimmune Therapeutics, INC. | $75.99 | 2024-2025 | Zenpep |
| Ars Pharmaceuticals Operations, INC. | $50.53 | 2025 | Neffy |
| Alcresta Therapeutics, INC. | $46.00 | 2019-2025 | Relizorb |
| Teva Pharmaceuticals USA, INC. | $40.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.14 | 2019 | |
| Eisai INC. | $35.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.76 | 2023 | Elaprase |
| Monaghan Medical Corporation | $34.43 | 2022-2025 | Aerobika |
| Insmed, INC. | $32.89 | 2025 | Brinsupri |
| Vivus LLC | $23.19 | 2022 | |
| Resmed Corp | $18.82 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudhakar Reddivalam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.